Clinical Trials DEA Research and Development 
WeedAdvisor
JULY 4, 2019
Despite mounting evidence into cannabis’ therapeutic benefits, the DEA continues to close its eyes and plug its ears, constantly claiming that there is not enough research to support its medicinal value, according to Marijuana Moment. It could be argued that the DEA is hesitant for the sake of public safety. A Vicious Circle.
The Cannigma
JUNE 14, 2021
For more than 50 years, if you wanted to do cannabis research in the United States, federal law said you had to get the cannabis from the University of Mississippi. We are absolutely ecstatic,” George Hodgin, the CEO of the Castroville, California based Biopharmaceutical Research Co. Junk’ cannabis ‘ill-suited for clinical trials’.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
NORML
MARCH 1, 2019
Currently, the sole federally licensed producer of cannabis for clinical research is the University of Mississippi. ” The agency said that the policy change was necessary because the existing system provided “no clear legal pathway for commercial enterprises to produce marijuana for product development.”
SpeedWeed
JULY 23, 2021
Denver is expanding Alzheimer’s research through the efforts of local company MedPharm. . The company plans to move forward with research efforts through a special Schedule I Researcher Licenses given specifically to the company by the Drug Enforcement Administration. Denver Company Moves Forward with Research License .
Veriheal
JUNE 29, 2021
Did we ever stop to think that if we could legally utilize the plants in the first place that perhaps we wouldn’t develop terminal illnesses at such a high rate? The lawsuit came after the DEA denied their application to utilize a synthetic form of psilocybin under the RTT laws. Introducing the Right to Try Act.
Veriheal
JUNE 30, 2023
A study investigated psilocybin’s effect on alcohol addiction, the FDA outlined best practices for future psychedelic research, and the NCAA is inching toward cannabis policy change. For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial.
Cannabis Law Report
FEBRUARY 10, 2022
Court of Appeals for the Ninth Circuit dismissed a petition for review of a Drug Enforcement Administration (DEA) response to an attorney’s letter seeking advice and guidance on how a physician could administer psilocybin to a terminally ill patient without incurring liability under the Controlled Substances Act (CSA). By Allison Campbell.
Expert insights. Personalized for you.
111 
Let's personalize your content